[1] Luzuriaqa K, Sullivan JL. Infectious mononucleosis. N Engl J Med, 2010,362:1993-2000. [2] Thorley-Lawson DA,Gross A.Persistence of the Epstein‐Barr virus and the origins of associated lymphomas.N Engl J Med, 2004,350: 1328-1337. [3] Fox CP, Shannon-lowe C, Gothard P, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis, 2010, 51: 66-69. [4] 轶群,马进,方宁宁,等.经典型霍奇金淋巴瘤p16和p53蛋白表达与EB病毒感染相关性研究.中华肿瘤防治杂志,2015,22:1614-1618. [5] Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol, 2005, 80: 64-69. [6] Henter JI,Horne A,Aricoó M,et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer,2007,48:124- 131. [7] Henter JI, Samuelsson-Horne A, Aricò M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemot-herapy and bone marrow transplantation. Blood, 2002,100:2367-2373. [8] Cohen JI,Jaffe ES,Dale JK et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28- year experience in the United States. Blood,2011,117: 5835-5849. [9]Arai A. Advances in the study of chronic active epstein-barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development. Front Pediatr, 2019, 5: 7-14. [10] Schwarzmann F, Von Baehr R, Jager M, et al. A case of severe chronic active infection with Epstein-Barr virus: immunologic deficiencies associated with a lytic virus strain. Clin Infect Dis, 1999, 29: 626-631. [11] 刘焱,黄静,孙凌云,等.系统性红斑狼疮患者抗EB病毒抗体表达研究[J].中华风湿病学杂志,2011,15:291-295 [12] Biron CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol, 1999, 17: 189-220 [13] Azzi T, Lünemann A, Murer A, et al. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood, 2014, 124: 2533-2543. [14] Murakami M,Hashida Y,Imajoh M,et al. PCR array analysis of gene expression profiles in chronic active Epstein-Barr virus infection. Microbes Infect,2014,16:581-586. [15] Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol, 2002,117:259-267. [16] Khan G. Screening for Epstein-Barr virus in Hodgkin' s lymphoma. Methods Mol Biol, 2009,511: 311-322. [17] Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood, 2012, 119: 673-686. [18] Kimura H. Differences between T cell-type and natural kill cell type chronic active Epstein-Barr virus infection. J Infect Dis, 2005,191: 531-539. [19] Paik JH, Choe JY, Kim H, et al. Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications. Leuk Lymphoma, 2017, 58:53-63. [20] Bollard CM, Cohen JI. How I treat T-cell chronic active Epstein -Barr virus disease. Blood, 2018,131:2899-2905. [21] Sawada A, Inoue M, Kawa K. How we treat chronic Epstein-Barr virus infection. Int J Hematol, 2017,105: 406-418. |